Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii

International Journal of Antimicrobial Agents

Volumn 40, Issue 4, 2012, Pages 332-336

  Mutlu Yilmaz, Esmeray ^a   Sunbul, Mustafa ^a   Aksoy, Abdurrahman ^a   Yilmaz, Hava ^a   Guney, Akif Koray ^a   Guvenc, Tolga ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Colistin; Rat pneumonia model; Tigecycline; XDR Acinetobacter baumannii

Indexed keywords

COLISTIMETHATE; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; COLISTIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; LUNG; MINOCYCLINE; PNEUMONIA, BACTERIAL; RATS; RATS, WISTAR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866039806     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.06.003     Document Type: Article

References (29)

1. J.Y. Song, H.J. Cheong, J. Lee, A.K. Sung, and W.J. Kim Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model Int J Antimicrob Agents 33 2009 33 39
2. A. Montero, J. Ariza, X. Corbella, A. Domenech, C. Cabellos, and J. Ayats Efficacy of colistin versus β-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii Antimicrob Agents Chemother 46 2002 1946 1952
3. R. Jain, and L.H. Danziger Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians Ann Pharmacother 38 2004 1449 1459
4. A.P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, and C.G. Giske Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clin Microbiol Infect 18 2012 268 281
5. P.J. Petersen, P. Labthavikul, C.H. Jones, and P.A. Bradford In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis J Antimicrob Chemother 57 2006 573 576
6. J.Y. Song, S.Y. Kee, I.S. Hwang, Y.B. Seo, H.W. Jeong, and W.J. Kim In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii J Antimicrob Chemother 60 2007 317 322
7. N. Petrosillo, E. Ioannidou, and M.E. Falagas Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies Clin Microbiol Infect 14 2008 816 827
8. A. Montero, J. Ariza, X. Corbella, A. Doménech, C. Cabellos, and J. Ayats Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model J Antimicrob Chemother 54 2004 1085 1091
9. T.Y. Tan, L.S. Ng, E. Tan, and G. Huang In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates J Antimicrob Chemother 60 2007 421 423
10. C.K. Murray, and D.R. Hospenthal Treatment of multidrug resistant Acinetobacter Curr Opin Infect Dis 18 2005 502 506
11. M.H. Scheetz, C. Qi, J.R. Warren, M.J. Postelnick, T. Zembower, and A. Obias In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii Antimicrob Agents Chemother 51 2007 1621 1626
12. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M07-A8. Wayne, PA: CLSI; 2009.
13. C.R. Bonapace, R.L. White, L.V. Friedrich, and J.A. Bosso Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods Diagn Microbiol Infect Dis 38 2000 43 50
14. P. Koomanachai, A. Kim, and D.P. Nicolau Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model J Antimicrob Chemother 63 2009 982 987
15. J.M. Entenza, and P. Moreillon Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies Int J Antimicrob Agents 34 2009 8.e1-9
16. E.S. Moland, D.W. Craft, S. Hong, S. Kim, L. Hachmeister, and S.D. Sayed In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy Antimicrob Agents Chemother 52 2008 2940 2942
17. T.A. Russo, J.M. Beanan, R. Olson, U. MacDonald, N.R. Luke, and S.R. Gill Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology Infect Immun 76 2008 3577 3586
18. M.L. Joly-Guillou, M. Wolff, J.J. Pocidalo, F. Walker, and C. Carbon Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem Antimicrob Agents Chemother 41 1997 345 351
19. M. Bernabeu-Wittel, C. Pichardo, A. García-Curiel, M.E. Pachón-Ibáñez, J. Ibáñez-Martínez, and M.E. Jiménez-Mejías Pharmacokinetic/pharmacodynamic assessment of the in vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia Clin Microbiol Infect 11 2005 319 325
20. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents; tentative guideline. Document M26-T. Villanova, PA: NCCLS; 1992.
21. D. Plachouras, M. Karvanen, L.E. Friberg, E. Papadomichelakis, A. Antoniadou, and I. Tsangaris Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria Antimicrob Agents Chemother 53 2009 3430 3436
22. R. Imberti, M. Cusato, P. Villani, L. Carnevale, G.A. Iotti, and M. Langer Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration Chest 138 2010 1333 1339
23. N. Markou, M. Fousteri, S.L. Markantonis, E. Boutzouka, E. Tsigou, and G. Baltopoulo Colistin penetration in the alveolar lining fluid of critically ill patients treated with IV colistimethate sodium Chest 139 2011 232 233
24. J. Li, C.R. Rayner, R.L. Nation, R.J. Owen, D. Spelman, and K.E. Tan Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii Antimicrob Agents Chemother 50 2006 2946 2950
25. F.S. Taccone, H. Rodriguez-Villalobos, D. De Backer, V. De Moor, J. Deviere, and J.L. Vincent Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline Eur J Clin Microbiol Infect Dis 25 2006 257 260
26. J.M. Pouge, J. Lee, D. Marchaim, V. Yee, J.J. Zhao, and T. Chopra Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system Clin Infect Dis 53 2011 879 884
27. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no. 2: prevalence and trends. Geneva, Switzerland: WHO; 2000. WHO/CDS/TB/2000.278.
28. F.G. Rios, C.M. Luna, B. Maskin, A. Saenz Valiente, M. Lloria, and S. Gando Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Eur Respir J 30 2007 307 313
29. G. Luo, L. Lin, A.S. Ibrahim, B. Baquir, P. Pantapalangkoor, and R.A. Bonomo Active and passive immunization protects against lethal, extreme drug-resistant Acinetobacter baumannii infection PLoS One 7 2012 e29446